Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Sep 01, 2006 (Vol. 26, No. 15)

GNN-Quick Guide to Sequenced Genomes

URL:www.genomenewsnetwork.org/resources/sequenced_genomes/genome_guide_p1.shtml
  • Very tidy design
  • None
When I was a kid, I was a big collector of baseball cards. Every night, I’d go through them and admire the players and their accomplishments. I get a similar feeling looking through the GNN site (clever title, by the way), with its up-close-and-personal treatment of organisms whose genomes have been sequenced. Each entry has a picture of the species accompanied by a short profile of the organisms, which is not an awful lot different from what used to be on the back of baseball cards. In addition, clicking on a picture brings up an even more in-depth description of the organism. Last, it’s hard to believe, but to cover the topic of sequenced genomes, it is now necessary to break them up alphabetically into five groups. I’m not sure if that news is good or bad.
  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »